Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 8

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 8
---
 part of our strategy. Some of the more significant risks include the following:

our financial results, including our ability to generate earnings and achieve and sustain profitability (as of June 30, 2025, we had an accumulated deficit of approximately $40.2 million, which was comprised of approximately $12.4 million of accumulated deficit of SkinJect as of September 30, 2023, the day after it became a subsidiary of the Company, and approximately $27.8 million of deficit accumulated by the Company on a consolidated basis since September 30, 2023), may vary significantly from forecasts and from period to period;

the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates

we may not successfully integrate Antev into our business and operations or successfully develop Teverelix;

our ability to market, commercialize, achieve market acceptance for and sell our products and product candidates, our ability to develop, manage and maintain our direct sales and marketing organizations;

our ability to continue as a going concern and if we are unable to obtain additional financing from outside sources and/or eventually generate enough revenues, we may be forced to curtail or discontinue our operations;

our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing;

market risks regarding consolidation in the healthcare, pharmaceutical and biotech/life sciences industry;

the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products significantly declines;

our ability to adequately protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

<div align='center'>2</div>

the fact that product quality issues or product defects may harm our business, any product liability claims; and

the regulatory, legal and certain operating risks that our operations subject us to.

Please see "Risk Factors" for a discussion of these and other factors you should consider before making an investment in our securities.

Corporate Structure

An organizational chart showing our basic corporate structure is set forth below (SkinJect and Medicus Pharma Inc. are 100% owned and Antev is 98.6% owned by Medicus Pharma Ltd.):

Corporate History and Information

Our company (formerly, Interactive Capital Partners Corporation) was incorporated pursuant to the Business Corporations Act (Ontario) on April 30, 2008 under the name Interactive Capital Partners Corporation. Prior to the Business Combination (as defined below), the Company existed as a shell